Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 plus osimertinib for HER2-mediated resistance in EGFR-mutant NSCLC
NL-OMON55787Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine and osimertinib in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Objective response rate after 3 months. Started Jan 2019; status: active, not recruiting.
02
Drugs
trastuzumab emtansineosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55787.